Next Tuesday April 28th Fundació ACE will host a 1-hour webinar on COVID19, sex differences and clinical trials.
The speaker will be Dr. Maria Teresa Ferretti from the Women’s Brain Project, who will reflect upon COVID-19, sex differences and clinical trials.
Dr. Ferretti will be introduced by Dr. Mercè Boada, medical director of Fundació ACE.
About the speaker
Maria Teresa is a neuroimmunologist and science advocate with 10-year+ international experience in the field of Alzheimer’s disease and a unique expertise on sex and gender differences.
After a master in Pharmaceutical Chemistry in 2005 (University of Cagliari, Italy) and a stage at the Center of Excellence for Drug Discovery of GlaxoSmith&Kline (Harlow, England), she obtained a PhD in Pharmacology and Therapeutics at McGill University (Montreal, Canada) in 2011 with a thesis on the role of inflammation in early, pre-plaques stages of Alzheimer’s Disease.
In 2011 she moved back to Europe and joined the Nitsch’s lab (University of Zurich, Switzerland) as postdoc and group leader. In her research there, Maria Teresa led a small team, which employed single-cell, multidimensional deep immunophenotyping (with standard flow-cytometry and CyTOF) to identify novel biomarkers for increasing individual level prediction of cognitive decline and Alzheimer’s.
In 2016 Maria Teresa co-founded the non-profit organization called ‘Women’s Brain Project’ (WBP, CHE-369.271.906), advocating for sex-sensitive precision medicine for brain and mental diseases such as Alzheimer, migraine, multiple sclerosis, depression etc (www.womensbrainproject.com). Her work as WBP Chief Scientific Officer has led to several scientific publications in leading journals including Nature and PNAS, two TED-x talks, and coverage by both the national (Sonntagszeitung, SwissInfo, NZZ) and the international press (including BBC, The Independent, Sciences et Avenir, Financial Times).